VRCA Share Price Performance
US$4.38
-0.04 (-0.95%)
70.8% undervalued intrinsic discount
US$15.00
Fair Value
Price US$4.38
AnalystConsensusTarget US$15.00
AnalystLowTarget US$10.00
AnalystHighTarget US$20.00
Fair ValueUS$15.00
Share Pricen/a
Verrica Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
VRCA Community Narratives
AN
Fair Value US$15 70.8% undervalued intrinsic discount
In-office Dermatology Access And Global Trials Will Shape Markets
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$10 56.2% undervalued intrinsic discount
Restrictive Payer Policies Will Limit Dermatology Revenues But Spur Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$20 78.1% undervalued intrinsic discount
Aging Global Population And Patient-Friendly Solutions Will Expand Dermatology Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
In-office Dermatology Access And Global Trials Will Shape Markets
Key Takeaways Expanding demand for non-invasive dermatology treatments and broadening pharmacy access are driving revenue growth and improved margins for Verrica. Advancing clinical pipeline and strategic partnerships support future revenue streams with minimal shareholder dilution and greater operating efficiency.Read more
81
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$15
70.8% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
6.62x
Price in 2028
US$9.68
Restrictive Payer Policies Will Limit Dermatology Revenues But Spur Recovery
Key Takeaways Heightened reimbursement restrictions and regulatory scrutiny may limit market expansion and erode pricing power, increasing revenue and margin volatility. Heavy dependence on a single key product, combined with funding pressures and pipeline delays, threatens long-term earnings growth and financial stability.Read more
18
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$10
56.2% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
11.58x
Price in 2028
US$6.45
Aging Global Population And Patient-Friendly Solutions Will Expand Dermatology Markets
Key Takeaways YCANTH's rapid adoption and strong physician engagement position Verrica for outsized revenue growth and market leadership in both pediatric and adult dermatology. Global rights, strategic partnerships, and platform advantages enhance financial stability, open new royalty streams, and could make Verrica an attractive acquisition target.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
78.1% undervalued intrinsic discount
Fair Value
Profit Margin
23.22%
Future PE
9.45x
Price in 2028
US$23.17
Trending Discussion
Recently Updated Narratives
AN
In-office Dermatology Access And Global Trials Will Shape Markets
Fair Value: US$15 70.8% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Restrictive Payer Policies Will Limit Dermatology Revenues But Spur Recovery
Fair Value: US$10 56.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Global Population And Patient-Friendly Solutions Will Expand Dermatology Markets
Fair Value: US$20 78.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Verrica Pharmaceuticals Inc. Key Details
About VRCA
- Founded
- 2013
- Employees
- 76
- CEO
- WebsiteView website
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
